Impurity profile study of loratadine

J Pharm Biomed Anal. 2003 Apr 24;32(1):29-39. doi: 10.1016/s0731-7085(03)00056-6.

Abstract

Three unknown impurities in loratadine bulk drug at levels below 0.1% (ranging from 0.05 to 0.1%) were detected by a simple isocratic reversed-phase high performance liquid chromatography (HPLC). These impurities were isolated from mother liquor sample of loratadine using reversed-phase preparative HPLC. Based on the spectral data (IR, NMR and MS) the structures of these impurities were characterized as 11-(N-carboethoxy-4-piperidylidene)-6,11-dihydro-5H-benzo(5,6) cyclopenta(1,2-b)-pyridine (I), 8-bromo-11-(N-carboethoxy-4-piperidylidene)-6,11-dihydro-5H-benzo(5,6) cyclopenta (1,2-b)-pyridine (II) and 8-chloro-11-(N-carboethoxy-4-piperidylidene)-5H-benzo(5,6) cyclopenta (1,2-b)-pyridine (III). The synthesis of these impurities was discussed.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chromatography, High Pressure Liquid
  • Drug Contamination
  • Histamine H1 Antagonists, Non-Sedating / analysis
  • Histamine H1 Antagonists, Non-Sedating / chemistry*
  • Loratadine / analysis
  • Loratadine / chemistry*
  • Magnetic Resonance Spectroscopy
  • Mass Spectrometry
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Spectroscopy, Fourier Transform Infrared

Substances

  • Histamine H1 Antagonists, Non-Sedating
  • Loratadine